Abstract:Objective To observe the safety and efficacy of regime that based on aqueous cytomegalovirus-DNA (CMV-DNA) load and IL-8 determination for therapeutic monitoring and local treatment cessation of cytomegalovirus retinitis (CMVR) patients after allogeneic hematopoietic stem cell transplantation (HSCT).Methods A prospective case series study.A total of 14 CMVR patients (22 eyes) after allogeneic HSCT diagnosed in Ophthalmology Department of Peking University People's Hospital between January 2016 and December 2018 were involved in this study.All patients were CMV-DNA seronegative at baseline and were treated with intravitreous injection of ganciclovir (IVG,3 mg in 0.05 ml) twice per week for 4 times in the induction stage and once a week in the maintenance stage.Aqueous humor sample was collected during the first time of IVG every week.CMV-DNA and the level of IL-8 were measured by real time quantitative PCR and ELISA,respectively.During follow-up,negative CMV-DNA (＜ 103/ml) or level of IL-8 ＜ 30 pg/ml in aqueous sample was set as local treatment cessation.Then patients were followed every 2 weeks for at least 6 months.BCVA,intraocular pressure and fundus examination were taken for each visit.The BCVA examination was performed using the international standard visual acuity chart,which was converted into logMAR visual acuity.BCVA and intraocular pressure at the baseline and the last follow-up were compared by the Student t matching test.Results Of the 14 CMVR patients (22 eyes) after allogeneic HSCT,8 patients (16 eyes) were bilateral,6 patients (6 eyes) were unilateral.At the baseline,the mean logMAR BCVA was 0.814 ± 0.563,the intraocular pressure was 17.2 ± 7.8 mmHg (1 mmHg=0.133 kPa),the mean aqueous CMV-DNA load was (3.43 ± 4.96)× 105/ml,the mean level of IL-8 was 518 ± 541 pg/ml.At cessation of local treatment,the median number of intravitreal injections was 5 times.Nine eyes showed negative CMV-DNA in aqueous humor,of which,7 eyes showed negative IL-8 in aqueous.CMV-DNA could still be detected in 13 eyes,while IL-8 was negative.Only one eye's retinal lesion was completely quiet.Six months after local treatment cessation,the mean logMAR B CVA was 0.812 ± 0.691,the intraocular pressure was 14.8± 5.4 mmHg;which was not significantly different from baseline (t=-0.107,1.517;P=0.916,0.137).Recurrence of CMVR happened in only 1 eye because of systemic EB virus infection.Retinal lesions progressively improved and became completely quiet in all the remaining 20 eyes.In 22 eyes,iatrogenic vitreous hemorrhage occurred due to low platelet count during treatment (＜ 30 × 109/ml) in 4 eyes.When the treatment was terminated for 6 months,the fundus of hematoma absorption was clearly visible.At the time of CMVR diagnosis,there were 2 eyes (9％) with posterior subcapsular opacity,which may be caused by systemic glucocorticoid therapy after allogeneic HSCT.Conclusion Aqueous CMV-DNA load and level of IL-8 could be used as quantitative variables for monitoring the therapeutic effect and determining time for local treatment cessation for CMVR after HSCT safely and efficiently.

Diagnosis and Treatment on Cytomegalovirus Retinitis Associated with Acquired Immunodeficiency Syndrome

Spectral-domain Optical Coherence Tomography Finding in Cytomegalovirus Retinitis in AIDS Patients

A Clinical Study on Cytomegaloviral Retinitis as a Complication of AIDS

Clinical Characteristic and Treatment of Cytomegalovirus Retinitis in 80 Patients with Acquired Immunodeficiency Syndrome

Cytomegalovirus retinitis associated with acquired immunodeficiency syndrome

Clinical features of Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome and efficacy of the current therapy

Measuring adolescent care in general practice--successes, problems, and pitfalls.

Twenty-three Cases of Cytomegalovirus Infection in Acquired Immunodeficiency Syndrome

Prevalence and clinical management of cytomegalovirus retinitis in AIDS patients in shanghai, china

Cytomegalovirus-Immune Recovery Retinitis after Initiation of Highly Active Antiretroviral Therapy: A Case Series.

Pathogenesis and Treatment of Human Immunodeficiency Virus-Associated Cytomegalovirus Retinitis

Antiviral therapy for cytomegalovirus retinitis: A systematic review and meta-analysis

An Uncommon Concurrence of Cytomegalovirus Retinitis and Corneal Endotheliitis in an Immunocompromised HIV-Negative Patient

Analysis of Clinical Characteristics of Patients with Recurrent Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation

Systemic risk factors and epidemiology of cytomegalovirus retinitis status-post allogeneic bone marrow hematopoietic stem cell transplantation

Incidence, Risk Factors, and Outcomes of Cytomegalovirus Retinitis after Haploidentical Hematopoietic Stem Cell Transplantation

Clinical Characteristics of Initial Ophthalmic Manifestation of Patients in Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection

Cytomegalovirus and the eye

An Unusual Cytomegalovirus Ocular Manifestation in a Non-HIV Patient

Regime for Cytomegalovirus Retinitis Based on Aqueous Virology and Inflammatory Cytokine Determination

[Influent Factors for Treating Procedure of Cytomegalovirus Retinitis after Allogeneic Bone Marrow Hematopoietic Stem Cell Transplantation].